Prime Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRME research report →
Range $6 – $9
Price Chart
About the company
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule.
- CEO
- Allan Reine
- IPO
- 2022
- Employees
- 146
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on PRME
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $645.82M
- P/E
- -3.82
- PEG
- -0.09
- P/S
- 98.42
- P/B
- 80.53
- EV/EBITDA
- -4.44
- Div Yield
- 0.00%
- Gross Margin
- 48.80%
- Op Margin
- -2584.24%
- Net Margin
- -2497.56%
- ROE
- -286.97%
- ROIC
- -97.25%
Latest fiscal year · YoY change
- Revenue
- $4.63M+55.3%
- Gross Profit
- $-2,689,000-190.1%
- Op Income
- $-208,350,000
- Net Income
- $-201,142,000-2.7%
- EPS
- $-1.35+18.3%
- OCF Growth
- -32.3%
- FCF Growth
- -28.4%
- 52W High
- $5.91
- 52W Low
- $2.67
- 50D MA
- $3.73
- 200D MA
- $3.51
- Beta
- 2.15
- RSI (14)
- 47
- Avg Volume
- 4.60M
No earnings-call transcripts are available for PRME yet.
- Free Float
- 32.8%
- Shares Outstanding
- 181.92M
- Float Shares
- 59.60M
of shares held by institutions
195 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alphabet Inc. | 16.56M | 0 |
| Blackrock, Inc. | 10.72M | ▲ 1.11M |
| Ark Investment Management LLC | 10.04M | ▲ 1.69M |
| Vanguard Group Inc | 6.47M | ▲ 1.55M |
| State Street Corp | 6.15M | ▼ 1.43M |
| T. Rowe Price Investment Management, Inc. | 5.24M | ▼ 244.56K |
| Vanguard Capital Management LLC | 4.58M | ▲ 56.95K |
| Balyasny Asset Management L.P. | 3.97M | ▼ 154.28K |
| Goldman Sachs Group Inc | 3.43M | ▲ 2.46M |
| Casdin Capital, LLC | 3.17M | 0 |
| Woodline Partners LP | 3.00M | ▲ 591 |
| Amova Asset Management Americas, Inc. | 2.91M | ▲ 504.58K |
Held by 213 ETFs
Biggest fund positions in PRME by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Schenkein David P | other | 75,000 |
| Jun 5, 26 | Marrazzo Jeffrey D | other | 75,000 |
| Jun 5, 26 | NELSEN ROBERT | other | 75,000 |
| Jun 5, 26 | Kelly Michael Aaron | other | 75,000 |
| Jun 5, 26 | Foster-Cheek Kaye I | other | 75,000 |
| Jun 5, 26 | Chung Wendy | other | 75,000 |
| Jun 5, 26 | Cahill Thomas | other | 75,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 800,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 0 |
| Feb 26, 26 | Reine Allan | other | 1,300,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRME coverage
Recent articles, reports, and earnings notes.
Scribe Therapeutics IPO: What Investors Need to Know
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.

Top Gene Editing Stocks: Our 7 Picks for September 2026
A countdown of 7 gene editing stocks, with the top pick revealed last.
Want a deeper read on PRME?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
globenewswire.com · Nov 12
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 12
Cathie Wood Dumps the Last of Teradyne From Her Flagship Fund
247wallst.com · Nov 12
Prime Medicine Announces Pricing of Public Offering of Common Stock
globenewswire.com · Nov 10
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
globenewswire.com · Nov 10
Prime Medicine to Present at Jefferies Global Healthcare Conference
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.